In a stunning first, German researchers report that a young woman with multidrug-resistant ulcerative colitis entered complete remission after receiving CD19 CAR T-cell therapy—a treatment once thought unsuitable for UC. Just weeks after infusion, her symptoms vanished, biomarkers normalized, and mucosal healing began. While the follow-up is short and evidence rests on a single case, the outcome raises a provocative question: could CAR T therapy, long reserved for B-cell cancers and select autoimmune diseases, rewrite the future of UC care?
Keep Reading
Add A Comment